The FDA Removed the Black Box Warning on Hormone Therapy

For twenty-three years, the most prominent warning the FDA can put on a drug sat on every estrogen product used for menopause. In November 2025 the agency started taking it off. The reason it gives is worth reading closely, because it is not that new evidence arrived. It is that the old warning was never based on the drugs most women were being denied.

If you were told no in 2009, or in 2015, or two years ago, this is the article I would want you to read. Not because the answer is now automatically yes. Because you deserve to know what the no was actually based on.

What the FDA did, and when

This happened in stages, and the staging matters if you are trying to work out whether it applies to whatever you were prescribed or refused.

July 17, 2025 — An FDA expert panel met to review the class labeling on menopausal hormone therapy. Several panelists said plainly that the risks had been overstated.

November 10, 2025 — The FDA and HHS announced they would remove the broad boxed warnings covering cardiovascular disease, breast cancer and probable dementia. The agency's own language described the existing warnings as misleading without clinical context.

February 12, 2026 — The first six products were approved with new labels. Twenty-nine manufacturers had submitted proposed changes. The relabeling is still working its way through the rest.

Three things came off the boxed warning: cardiovascular disease, breast cancer, and probable dementia. A fourth change is less discussed and, in day-to-day practice, matters just as much. The instruction to use the lowest possible dose for the shortest possible time is gone. That single sentence shaped how a generation of women were treated, and it is the reason so many were tapered off something that was working.

Something else was added. The new labeling includes guidance that therapy is generally best begun before age 60, or within ten years of the onset of menopause.

Where the warning came from

In 2002, the Women's Health Initiative published an interim analysis that stopped a generation of hormone prescribing more or less overnight. It was a serious trial. It was not a small one. And its findings were real for the drug it studied.

Here is what it studied. Oral conjugated equine estrogen at 0.625 mg, taken with or without medroxyprogesterone acetate at 2.5 mg. Women aged 50 to 79, with a mean age of 63. In North America the average age of menopause is 51. So the average woman in that trial started hormone therapy roughly twelve years after her last period, at an age when arterial disease is often already established.

That is not the woman who walks into my office. She is 47, still having irregular cycles, sleeping badly, and wondering why she cannot think straight in meetings she used to run.

The gap between those two women is the whole story. And the FDA's own labeling said so at the time, in writing. The 2003 Prempro label states that other doses and other combinations were not studied in the trial, and then adds this:

"In the absence of comparable data, these risks should be assumed to be similar."

Assumed. Not measured. One oral formulation was tested, in older women, and the results were applied to every estrogen, at every dose, by every route, at every age. Patches carried a warning generated by a pill. Women in their late forties carried a warning generated in women in their sixties.

Prescribing collapsed. Most estimates put the drop at around 70 percent within a few years. Doctors trained after 2002, and I have met many, learned hormone therapy as something you talk patients out of.

What did not change

This is the part that gets skipped in the enthusiastic version of this story, so I will put it plainly.

Systemic estrogen-alone products keep a boxed warning for endometrial cancer in women who still have a uterus. That risk is real and it has never been in dispute. If you have a uterus and you are taking estrogen, you need progesterone alongside it to protect the uterine lining.

I will put this more firmly than the label does. In my practice, all women need progesterone — not only those who still have a uterus. Endometrial protection is the boxed-warning reason, and it is a real one. Progesterone does far more than that. It is vital for bone density, mood, and sleep. Anyone prescribing estrogen without addressing progesterone is not practicing carefully, black box or no black box.

Information about cardiovascular disease and breast cancer also remains in the product inserts. It moved out of the boxed warning. It did not vanish. The change is one of proportion, not of erasure.

Why the route matters

The trial that generated the warning used an oral estrogen. Anything swallowed goes through the liver before it reaches the rest of the body, and the liver responds by changing its production of clotting factors. Estrogen absorbed through the skin does not take that route.

Observational data have consistently associated transdermal estrogen with a lower clotting risk than oral estrogen. I want to be careful with that sentence, because observational is not the same as proven, and I am not going to overstate it in either direction. But it is one of the reasons that at Juvenis Medical I prescribe estrogen by topical and transdermal routes only. Not oral. I typically prescribe Bi-Est — a compounded combination of estradiol and estriol — because it is particularly protective to breast glandular tissue. That was my practice before the labeling changed and it is my practice now.

The same logic applies to the hormone itself. What the WHI tested was conjugated equine estrogen and a synthetic progestin. What I prescribe is Bi-Est plus bioidentical progesterone, compounded by a licensed pharmacy to the dose your labs call for. Whether that difference produces a different risk profile is still argued over honestly by people who know the literature well. It is not nothing, and it is not a marketing claim either.

Who this actually changes things for

The prescribing data suggest the shift was already happening before the FDA moved. An Epic Research analysis covering more than 163 million women in US outpatient care found hormone therapy use roughly doubled between 2017 and April 2026, from 1.7 percent to 3.6 percent. Among women aged 45 to 54, it nearly tripled. Use was flat until about 2022 and then climbed steeply.

Women found this before the labels caught up. They found it in podcasts and books and from each other, and a lot of them arrived at my office already better informed about the WHI than the last three doctors who dismissed them.

If any of these describe you, the ground has genuinely shifted:

• You asked about hormone therapy and were told the risks were too high, without a conversation about your age, your route of delivery, or your actual risk factors.
• You were put on something that helped, then tapered off it because of the lowest-dose-shortest-time instruction rather than because it stopped working.
• You are in your forties, still cycling, and were told to come back when you are properly menopausal.
• Your labs came back inside the reference range and the conversation ended there.

That last one is not a labeling problem, and no FDA announcement fixes it. A reference range describes a population. It does not describe you, and it certainly does not describe where you were five years ago compared to now.

The ten-year window is the part to act on

If you take one practical thing from all of this, take this. The new labeling points to starting within ten years of menopause onset, or before age 60. The benefit and risk balance in that window looks different from the balance for a woman starting fifteen years out, which is precisely the distinction the old warning flattened.

Which means the cost of waiting is not zero. If you are 49 and thinking about it, the decision in front of you is not the same decision you will face at 63, and it is worth having the conversation while the answer is still fully available to you.

That is not a reason to rush. It is a reason not to drift.

How we handle it here

Nothing about my process changed in November 2025, because it was never built on the boxed warning in the first place. It is built on labs.

Every protocol starts with a full panel, priced between $100 and $345 — estradiol, progesterone, testosterone, DHEA-S, a complete thyroid set including free T3 and reverse T3, cortisol, and metabolic markers. Over 70 factors. I go through the results with you myself before anything is prescribed, and we repeat the labs at six to eight weeks to see where your levels actually landed rather than where I hoped they would.

You can read the specifics on the menopause and perimenopause care page, and the thyroid side on the thyroid optimization page, since fatigue and brain fog are as easily thyroid as they are estrogen and I am not willing to guess between them.

One limit worth stating up front: hormone therapy by telehealth is available to Florida residents only. If you are outside Florida, you are welcome at the Oakland Park clinic in person, and non-controlled peptide therapy is available nationwide.

Questions I get asked

So the FDA now says hormone therapy is safe?
No, and be wary of anyone who tells you it does. The agency removed warnings it concluded were misleading for the population being warned. Whether it is right for you still depends on your history, your labs, and your contraindications.

I have a family history of breast cancer. Does this change my answer?
It changes the framing of the conversation, not the need to have it carefully. Personal and family history remains central to the decision, and there are women for whom I will not prescribe. That has not changed.

I am 58 and stopped my periods at 51. Am I inside the window?
On both counts, yes — under 60, and seven years out. That is a conversation worth having now rather than in three years.

Do I need to be in menopause to be treated?
No. Perimenopause is where a great many of the symptoms live, and it can run for years while your cycles are still happening. Being told to come back later is one of the more frustrating things women hear.

Is compounded the same as FDA-approved?
They are different regulatory categories and it is fair to ask. Compounded prescriptions are made by a licensed pharmacy to a specific dose for a specific patient, which is what allows the dose to follow your labs. I use licensed, accredited compounding pharmacies only, and I will tell you exactly which one your prescription comes from.